Tuberculin Skin Test Reversion following Isoniazid Preventive Therapy Reflects Diversity of Immune Response to Primary Mycobacterium tuberculosis Infection

Simple item page
dc.contributor.authorJohnson, Denise F.
dc.contributor.authorMalone, LaShaunda L.
dc.contributor.authorZalwango, Sarah
dc.contributor.authorOketcho, Joy Mukisa
dc.contributor.authorChervenak, Keith A.
dc.contributor.authorThiel, Bonnie
dc.contributor.authorMayanja-Kizza, Harriet
dc.contributor.authorStein, Catherine M.
dc.contributor.authorBoom, Henry W.
dc.contributor.authorLancioni, Christina L.
dc.date.accessioned2021-12-09T10:56:59Z
dc.date.available2021-12-09T10:56:59Z
dc.date.issued2014
dc.description.abstractRationale: Healthy household contacts (HHC) of individuals with Tuberculosis (TB) with Tuberculin Skin Test (TST) conversions are considered to harbor latent Mycobacterium tuberculosis (Mtb), and at risk for TB. The immunologic, clinical, and public health implications of TST reversions that occur following Isoniazid preventive therapy (IPT) remain controversial. Objectives: To measure frequency of TST reversion following IPT, and variation in interferon-gamma (IFN-c) responses to Mtb, in healthy Ugandan TB HHC with primary Mtb infection evidenced by TST conversion. Methods: Prospective cohort study of healthy, HIV-uninfected, TST-negative TB HHC with TST conversions. Repeat TST was performed 12 months following conversion (3 months following completion of 9 month IPT course) to assess for stable conversion vs. reversion. Whole blood IFN-c responses to Mtb antigen 85B (MtbA85B) and whole Mtb bacilli (wMtb) were measured in a subset (n = 27 and n = 42, respectively) at enrollment and TST conversion, prior to initiation of IPT. Results: Of 122 subjects, TST reversion was noted in 25 (20.5%). There were no significant differences in demographic, clinical, or exposure variables between reverters and stable converters. At conversion, reverters had significantly smaller TST compared to stable converters (13.7 mm vs 16.4 mm, respectively; p = 0.003). At enrollment, there were no significant differences in IFN-c responses to MtbA85B or wMTB between groups. At conversion, stable converters demonstrated significant increases in IFN-c responses to Ag85B and wMtb compared to enrollment (p = 0.001, p,0.001, respectively), while there were no significant changes among reverters. Conclusions: TST reversion following IPT is common following primary Mtb infection and associated with unique patterns of Mtb-induced IFN-c production. We have demonstrated that immune responses to primary Mtb infection are heterogeneous, and submit that prospective longitudinal studies of cell mediated immune responses to Mtb infection be prioritized to identify immune phenotypes protective against development of TB disease.en_US
dc.identifier.citationCitation: Johnson DF, Malone LL, Zalwango S, Mukisa Oketcho J, Chervenak KA, et al. (2014) Tuberculin Skin Test Reversion following Isoniazid Preventive Therapy Reflects Diversity of Immune Response to Primary Mycobacterium tuberculosis Infection. PLoS ONE 9(5): e96613. doi:10.1371/journal.pone.0096613en_US
dc.identifier.other10.1371
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/220
dc.language.isoenen_US
dc.publisherKatalin Andrea Wilkinsonen_US
dc.subjectTuberculosisen_US
dc.subjectTuberculinen_US
dc.subjectSkin Testen_US
dc.subjectimmunologicen_US
dc.subjectpublic healthen_US
dc.titleTuberculin Skin Test Reversion following Isoniazid Preventive Therapy Reflects Diversity of Immune Response to Primary Mycobacterium tuberculosis Infectionen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Tuberculin Skin Test Reversion following Isoniazid Preventive Therapy Reflects Diversity of Immune Response to Primary Mycobacterium tuberculosis Infection.pdf
Size:
670.29 KB
Format:
Adobe Portable Document Format
Description:
pdf
Download
Collections
Medical and Health Sciences